SCHEMBL6404292

SCHEMBL6404292

Nc1nc(=O)n([C@@H]2O[C@H](CO)CS2)cc1F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALB P02768 3/20 0.64
POLG P54098 1/20 0.46
LMNA P02545 4/20 0.40
PDE3A Q14432 3/20 0.40
CACNA1F O60840 2/20 0.40
MAPT P10636 2/20 0.40
CACNA1D Q01668 2/20 0.40
CACNA1S Q13698 2/20 0.40
CACNA1C Q13936 2/20 0.40
DCK P27707 11/20 0.36
DNMT1 P26358 2/20 0.33
ADRB1 P08588 1/20 0.33
PDE4D Q08499 1/20 0.33
SLC29A1 Q99808 1/20 0.33
MTOR P42345 2/20 0.32
THRB P10828 1/20 0.32
MDM2 Q00987 1/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
GMNN O75496 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12125352 0.80 ALB (0.48) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine SCHEMBL12202574 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine SCHEMBL3722124 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine, (+/-)- SCHEMBL122131 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine SCHEMBL5427218 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine SCHEMBL267686 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine SCHEMBL39708 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine SCHEMBL6903677 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine SCHEMBL22413085 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F
Emtricitabine SCHEMBL6362885 0.78 ALB (1.00) ALBPOLGLMNAPDE3ACACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050192299-A1 Method of treating or preventing hepatitis B virus CHENG YUNG-CHI (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192299-A1 Method of treating or preventing hepatitis B virus CDA, DCTD, TTPA ALB 720/4885POLG 807/4885LMNA 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.